ADC Therapeutics

166 articles with ADC Therapeutics

• ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

  3/15/2023

  ADC Therapeutics SA announced its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, has been filed with the U.S. Securities and Exchange Commission.

• ADC Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

  3/1/2023

  ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the Cowen 43rd Annual Health Care Conference in Boston, MA, on Tuesday, March 7th at 2:50 p.m. ET.

• ADC Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

  2/28/2023

  ADC Therapeutics SA today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided business updates.

• ADC Therapeutics to Host Fourth Quarter and Year-End 2022 Financial Results Conference Call on February 28, 2023

  2/21/2023

  ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, February 28, 2023 at 8:30 a.m. ET to report financial results for the fourth quarter and year-end 2022 and provide business updates.

• ADC Therapeutics Announces Pricing of Underwritten Offering by a Selling Shareholder

  2/2/2023

  ADC Therapeutics SA today announced the pricing of an underwritten offering of 12,000,000 common shares of the Company currently owned by A.T. Holdings II Sàrl (the “Selling Shareholder”), an affiliate of Auven Therapeutics Holdings L.P., at a price of $5.00 per share.

• ADC Therapeutics to Participate in February Investor Conferences

  2/1/2023

  ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in February.

• ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

  1/4/2023

  ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 11th at 3:00 p.m. PT.

• ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer

  1/3/2023

  ADC Therapeutics SA announced the appointment of industry veteran Mohamed Zaki, MD, PhD, as Chief Medical Officer, effective January 3, 2023. He will serve on the Company’s executive leadership team.

• ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

  12/21/2022

  ADC Therapeutics SA and Swedish Orphan Biovitrum AB announced the European Commission has granted conditional marketing authorization for the use of ZYNLONTA® for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

• ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer

  12/19/2022

  ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Jose “Pepe” Carmona as Chief Financial Officer (CFO), effective December 19, 2022.

• Biocytogen Enters into Antibody Agreement with ADC Therapeutics

  11/28/2022

  Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA.

• ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

  11/8/2022

  ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates.

• ADC Therapeutics to Participate in the Jefferies 2022 London Healthcare Conference

  11/7/2022

  ADC Therapeutics SA announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15th at 9:45 a.m. GMT.

• 

  Movers & Shakers: Ambrx, ADC Therapeutics, ImmunoGen and More get New C-Suites

  11/4/2022

  The executive shuffle continues across the biopharma industry as companies shore up leadership needs with these Movers & Shakers.

• ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting

  11/3/2022

  ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on several of its antibody drug conjugates (ADCs), including ZYNLONTA® (loncastuximab tesirine-lpyl), camidanlumab tesirine (Cami) and ADCT-602, will be presented at the 64th American Society of Hematology (ASH) Annual Meeting, which will be held in New Orleans, Louisiana from December 10-13, 2022.

• IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma

  11/2/2022

  IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, and ADC Therapeutics SA (NYSE: ADCT) today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate the combination of imvotamab, IGM’s novel IgM CD20 x CD3 T cell engaging bispecific antibody, and ZYNLONTA®.

• ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer

  11/1/2022

  ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Kristen Harrington-Smith as Chief Commercial Officer, effective November 17, 2022.

• ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022

  10/31/2022

  ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 8, 2022 at 8:30 a.m. ET to report financial results for the third quarter 2022 and provide business updates.

• ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)

  9/21/2022

  ADC Therapeutics SA (NYSE: ADCT) today announced that ZYNLONTA® (loncastuximab tesirine-lpyl) and camidanlumab tesirine (Cami) abstracts have been accepted for presentation at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022).

• ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

  9/16/2022

  ADC Therapeutics SA (NYSE: ADCT) and Swedish Orphan Biovitrum AB (Sobi®) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the marketing authorization of ZYNLONTA® (loncastuximab tesirine) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).